RenovoRx, Inc. (RNXT)

NASDAQ:
RNXT
| Latest update: Apr 15, 2026, 5:36 PM

Stock events for RenovoRx, Inc. (RNXT)

RenovoRx's stock price has seen fluctuations over the past six months. Key events impacting the stock include the release of financial results, clinical trial updates, commercialization progress, and a patent allowance. The company reported its full-year 2025 financial results on March 30, 2026. The DMC for the Phase III TIGeR-PaC trial recommended continuing the study based on an interim data review. The company has reported growing clinical adoption and market demand for RenovoCath. RenovoRx secured its first notice of allowance for a Japanese patent covering its RenovoCath device.

Demand Seasonality affecting RenovoRx, Inc.’s stock price

The available information does not explicitly indicate demand seasonality for RenovoRx's products and services. The company has reported growing clinical demand and market demand for its RenovoCath device, suggesting a consistent and growing need for its targeted drug delivery solutions in oncology.

Overview of RenovoRx, Inc.’s business

RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted oncology therapies and commercializing its RenovoCath device. The company's core business revolves around its TAMP therapy platform, designed for targeted therapeutic delivery to minimize toxicities. Major products include RenovoCath, an FDA-cleared device for delivering fluids to selected sites, and intra-arterial gemcitabine (IAG) via RenovoCath, a drug-device combination being evaluated in a Phase III trial for pancreatic and bile duct cancer.

RNXT’s Geographic footprint

RenovoRx, Inc. is headquartered in Mountain View, California. The company has been expanding its commercial footprint across the United States, with its RenovoCath device approved for purchase by an increasing number of cancer centers. RenovoRx also secured its first notice of allowance for a Japanese patent covering its RenovoCath device in April 2026.

RNXT Corporate Image Assessment

RenovoRx has received positive recognition in the past year, enhancing its brand reputation. RenovoRx was named to Fast Company's annual list of the World's Most Innovative Companies of 2026. The growing clinical adoption of RenovoCath and increasing physician interest in targeted intra-arterial drug delivery also contribute positively to its reputation.

Ownership

RenovoRx, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. Approximately 10.97% to 19.78% of the company's stock is owned by institutional investors, 3.54% by insiders, and a significant portion (76.67%) by public companies and individual investors. Major institutional owners and shareholders include AIGH Capital Management LLC, Vanguard Group Inc, and Geode Capital Management, Llc, among others.

Expert AI

Show me the sentiment for RenovoRx, Inc.
What's the latest sentiment for RenovoRx, Inc.?

Price Chart

$1.00

2.91%
(1 month)

Top Shareholders

AIGH Investment Partners LLC
7.73%
The Vanguard Group, Inc.
4.38%
AWM Investment Co., Inc.
2.43%
Bleichroeder Holdings LLC
1.64%
Geode Holdings Trust
1.01%
Wealthspire GP LLC
0.69%
Renaissance Technologies Holdings Corp.
0.32%
Nixon Peabody LLP
0.27%

Trade Ideas for RNXT

Today

Sentiment for RNXT

News
Social

Buzz Talk for RNXT

Today

Social Media

FAQ

What is the current stock price of RenovoRx, Inc.?

As of the latest update, RenovoRx, Inc.'s stock is trading at $1.00 per share.

What’s happening with RenovoRx, Inc. stock today?

Today, RenovoRx, Inc. stock is down by -2.91%, possibly due to news.

What is the market sentiment around RenovoRx, Inc. stock?

Current sentiment around RenovoRx, Inc. stock is negative, based on recent news, trading volume, and analyst opinions.

Is RenovoRx, Inc.'s stock price growing?

Over the past month, RenovoRx, Inc.'s stock price has decreased by -2.91%.

How can I buy RenovoRx, Inc. stock?

You can buy RenovoRx, Inc. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol RNXT

Who are the major shareholders of RenovoRx, Inc. stock?

Major shareholders of RenovoRx, Inc. include institutions such as AIGH Investment Partners LLC (7.73%), The Vanguard Group, Inc. (4.38%), AWM Investment Co., Inc. (2.43%) ... , according to the latest filings.